32.4 C
New Delhi
April 19, 2021
PowerNews TV
Health

Phase III trials of Oxford Coronavirus vaccine to conclude by November, mass production likely by 2021

Amid the row over the Russian COVID-19 vaccine, which is looked upon as a health hazard by many, due to unanswered human trial queries, the Oxford University vaccineis making great headway. It is one of the leading vaccine candidates in the world seen as a panacea to the dreaded virus.

There is good news on this vaccine, as currently, it is in phase III of its trials. According to latest reports, it will be the first vaccine to get launched for the in 2020 and most likely will be available for public deployment by 2021.

Along with the world where phase III clinical trials are being conducted in research facilities across the UK, US, Brazil, and South Africa, India is also expected to start trials from next week in collaboration with Serum Institute of India.

Known as AZD-12222, the Oxford University backed vaccine, was one of the first to begin the human trial stage as well as start late-stage trials. Even the W.H.O. has reposed great hope in this vaccine terming as the safest in the race. Whereas the Russian vaccine-Sputnik V has been considered not a safe option by scientists.

The Oxford vaccine is being made by using a non-replicating viral strain.  There were reports that it is going to be launched in 2020. However, the latest from the Oxford vaccine research institute, is that it is going to be launched only next year.

The researchers are optimistic about seeing the end of clinical trials by November or early December. It is learned that Oxford Researchers have also signed a pact with Mexico and Argentine authorities to scale up production in the first quarter of 2021.

Even India’s top drug regulatory body has also granted permission to Serum Institute of India (SII) to conduct phase II and III human trials for the Oxford COVID-19 vaccine in India.

According to reports, each subject will be administered two doses four weeks apart (first dose on day one and second dose on day 29) following which the safety and immunogenicity will be assessed at predefined intervals.

Related posts

Covaxin, Bharat Biotech’sCOVID-19 vaccine to conduct Phase-3 Trials in Lucknow, Gorakhpur

POWER NEWS TEAM

India still far away from COVID-19 herd immunity, shun complacency, says Health Minister

POWER NEWS TEAM

COVID-19 vaccine may be ready by December: Adar Poonawala

POWER NEWS TEAM

Leave a Comment